Structure-based drug design meets the ribosome.

The high-resolution structures of the bacterial ribosomal subunits and those of their complexes with antibiotics have advanced significantly our understanding of small-molecule interactions with RNA. The wealth of RNA structural data generated by these structures has allowed computational chemists to employ a drug discovery paradigm focused on RNA-based targets. The structures also show how target-based resistance affects antibiotics acting at the level of the ribosome. Not only are the sites pinpointed where different classes of antibiotics inhibit protein synthesis, but their orientations, relative dispositions, and unique mechanisms of action are also revealed at the atomic level. Both the 30S and the 50S ribosomal subunits have been shown to be "targets of targets", offering several adjacent, functionally relevant binding pockets for antibiotics. It is the detailed knowledge of these validated locations, or ribofunctional loci, plus the mapping of the resistance hot-spots that allow the rational design of next-generation antibacterials. When the structural information is combined with a data-driven computational toolkit able to describe and predict molecular properties appropriate for bacterial cell penetration and drug-likeness, a structure-based drug design approach for novel antibacterials shows great promise.

[1]  J. Murray,et al.  The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. , 2003, Journal of the American Chemical Society.

[2]  Walters Wp,et al.  Guiding molecules towards drug-likeness. , 2002 .

[3]  Eric Westhof,et al.  Crystal structure of geneticin bound to a bacterial 16S ribosomal RNA A site oligonucleotide. , 2003, Journal of molecular biology.

[4]  P. Nielsen,et al.  Design, synthesis and ribosome binding of chloramphenicol nucleotide and intercalator conjugates. , 2005, Bioorganic & medicinal chemistry letters.

[5]  B. Matthews,et al.  Docking molecules by families to increase the diversity of hits in database screens: Computational strategy and experimental evaluation , 2001, Proteins.

[6]  Gregor Blaha,et al.  Structures of MLSBK Antibiotics Bound to Mutated Large Ribosomal Subunits Provide a Structural Explanation for Resistance , 2005, Cell.

[7]  T. Earnest,et al.  Crystal Structure of the Ribosome at 5.5 Å Resolution , 2001, Science.

[8]  Gerhard Klebe,et al.  Recent developments in structure-based drug design , 2000, Journal of Molecular Medicine.

[9]  W. L. Jorgensen,et al.  Prediction of Properties from Simulations: Free Energies of Solvation in Hexadecane, Octanol, and Water , 2000 .

[10]  A. Yonath,et al.  Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin , 2004, Molecular microbiology.

[11]  E. Westhof,et al.  Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding a site. , 2002, Chemistry & biology.

[12]  Poul Nissen,et al.  The structures of four macrolide antibiotics bound to the large ribosomal subunit. , 2002, Molecular cell.

[13]  J. Quinn,et al.  Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Takayoshi Kinoshita,et al.  Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. , 2004, Journal of medicinal chemistry.

[15]  Mohammad Afshar,et al.  RNA as a drug target. , 2002, Progress in medicinal chemistry.

[16]  Ronald N. Jones,et al.  Linezolid Resistance since 2001: SENTRY Antimicrobial Surveillance Program , 2003, The Annals of pharmacotherapy.

[17]  Zukang Feng,et al.  The Nucleic Acid Database. , 2002, Acta crystallographica. Section D, Biological crystallography.

[18]  F. Murphy,et al.  Atomic structures of the 30S subunit and its complexes with ligands and antibiotics. , 2001, Cold Spring Harbor symposia on quantitative biology.

[19]  Rowland Rs.  Using X-ray crystallography in drug discovery. , 2002 .

[20]  C. Walsh.  Molecular mechanisms that confer antibacterial drug resistance , 2000, Nature.

[21]  T. Hermann,et al.  Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. , 2005, Angewandte Chemie.

[22]  Thomas A Steitz,et al.  Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. , 2003, Journal of molecular biology.

[23]  J. Blanchard,et al.  Molecular insights into aminoglycoside action and resistance. , 2005, Chemical reviews.

[24]  Mary Jane Ferraro,et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.

[25]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[26]  D. Batts.  Linezolid--a new option for treating gram-positive infections. , 2000, Oncology.

[27]  R. Kurumbail,et al.  Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. , 2003, Journal of medicinal chemistry.

[28]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[29]  V. Ramakrishnan,et al.  Insights into the decoding mechanism from recent ribosome structures. , 2003, Trends in biochemical sciences.

[30]  P. Darke,et al.  L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. , 1994, Journal of medicinal chemistry.

[31]  Ernest Frederick Gale,et al.  The Molecular basis of antibiotic action , 1972 .

[32]  C. Vonrhein,et al.  Structure of the 30S ribosomal subunit , 2000, Nature.

[33]  R. Berisio,et al.  Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants , 2003, Journal of bacteriology.

[34]  Robin Taylor,et al.  Life-science applications of the Cambridge Structural Database. , 2002, Acta crystallographica. Section D, Biological crystallography.

[35]  A. R. Srinivasan,et al.  The nucleic acid database. A comprehensive relational database of three-dimensional structures of nucleic acids. , 1992, Biophysical journal.

[36]  A. Murchie,et al.  The bacterial ribosome, a promising focus for structure-based drug design. , 2002, Current opinion in pharmacology.

[37]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[38]  Walter E. Hill,et al.  The Ribosome : structure, function, and evolution , 1990 .

[39]  F. Schluenzen,et al.  Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria , 2001, Nature.

[40]  T. Hermann.  Rational ligand design for RNA: the role of static structure and conformational flexibility in target recognition. , 2002, Biochimie.

[41]  R C Jackson.  Contributions of protein structure-based drug design to cancer chemotherapy. , 1997, Seminars in oncology.

[42]  E Westhof,et al.  Docking of cationic antibiotics to negatively charged pockets in RNA folds. , 1999, Journal of medicinal chemistry.

[43]  V. Ramakrishnan,et al.  The Structural Basis for the Action of the Antibiotics Tetracycline, Pactamycin, and Hygromycin B on the 30S Ribosomal Subunit , 2000, Cell.

[44]  R. Zarivach,et al.  Structural basis for the antibiotic activity of ketolides and azalides. , 2003, Structure.

[45]  Daniel N. Wilson,et al.  Species-specific antibiotic-ribosome interactions: implications for drug development , 2005, Biological chemistry.

[46]  W Patrick Walters,et al.  Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.

[47]  A Yonath,et al.  Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3 , 2001, The EMBO journal.

[48]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[49]  Jonathan W. Essex,et al.  A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..

[50]  R. Rowland.  Using X-ray crystallography in drug discovery. , 2002, Current opinion in drug discovery & development.

[51]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[52]  V. Ramakrishnan,et al.  Recognition of Cognate Transfer RNA by the 30S Ribosomal Subunit , 2001, Science.

[53]  E Westhof,et al.  Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. , 2001, Structure.

[54]  Barrett Jf.  Linezolid Pharmacia Corp. , 2000 .

[55]  Frank Schluenzen,et al.  Structural insight into the role of the ribosomal tunnel in cellular regulation , 2003, Nature Structural Biology.

[56]  Nicolas Foloppe,et al.  A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site. , 2004, Bioorganic & medicinal chemistry.

[57]  F. Schluenzen,et al.  Structure of Functionally Activated Small Ribosomal Subunit , 2000 .

[58]  Jackson Rc,et al.  Contributions of protein structure-based drug design to cancer chemotherapy. , 1997 .

[59]  T. Steitz,et al.  The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. , 2000, Science.

[60]  Frank Schluenzen,et al.  High Resolution Structure of the Large Ribosomal Subunit from a Mesophilic Eubacterium , 2001, Cell.

[61]  Lakshmi P Kotra,et al.  Design of novel antibiotics that bind to the ribosomal acyltransfer site. , 2002, Journal of the American Chemical Society.

[62]  V. Ramakrishnan,et al.  Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics , 2000, Nature.

[63]  M. Murcko,et al.  Guiding molecules towards drug-likeness. , 2002, Current opinion in drug discovery & development.

[64]  E Westhof,et al.  RNA as a drug target: chemical, modelling, and evolutionary tools. , 1998, Current opinion in biotechnology.

[65]  F. Schluenzen,et al.  Structure of Functionally Activated Small Ribosomal Subunit at 3.3 Å Resolution , 2000, Cell.

[66]  T. Steitz,et al.  The structural basis of ribosome activity in peptide bond synthesis. , 2000, Science.

[67]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[68]  J. Sutcliffe.  Improving on nature: antibiotics that target the ribosome. , 2005, Current opinion in microbiology.

[69]  Ellen R. Laird,et al.  Chppter 30. Recent advances in virtual ligand screening , 2003 .

[70]  M. Rybak,et al.  Daptomycin – a novel antibiotic against Gram-positive pathogens , 2004, Expert opinion on pharmacotherapy.

[71]  T. Hermann,et al.  Aminoglycoside‐Hybrid Ligands Targeting the Ribosomal Decoding Site , 2005, Chembiochem : a European journal of chemical biology.

[72]  Thomas Hermann,et al.  Novel Paromamine Derivatives Exploring Shallow‐Groove Recognition of Ribosomal‐ Decoding‐Site RNA , 2002, Chembiochem : a European journal of chemical biology.

[73]  Thomas Hermann,et al.  Novel Acyclic Deoxystreptamine Mimetics Targeting the Ribosomal Decoding Site , 2003, Chembiochem : a European journal of chemical biology.

[74]  H. Bartels,et al.  Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin , 2004, BMC Biology.